No Data
No Data
Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen
Morgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)
Oppenheimer Initiates Pharvaris(PHVS.US) With Buy Rating, Announces Target Price $38
Oppenheimer analyst Jeff Jones initiates coverage on $Pharvaris(PHVS.US)$ with a buy rating, and sets the target price at $38.According to TipRanks data, the analyst has a success rate of 32.7% and a
Pharvaris Is Maintained at Outperform by Oppenheimer
Pharvaris Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Pharvaris, Raises Price Target to $38
Oppenheimer analyst Justin Kim maintains Pharvaris with a Outperform and raises the price target from $36 to $38.
Pharvaris Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 125.52% Oppenheimer $36 → $38 Maintains Outperform 05/09/2024 83.98% Wedbush $35 → $31 Maintain
No Data